Immuron Limited is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. The results show that Immuron’s oral IMM-124E shows improvement in liver injury and significantly reduces blood levels of LPS (lipopolysaccharide), a known mediator of liver inflammation in patients with NASH. The discovery could have far-reaching opportunities for the effective treatment of a broad range of diseases relating to LPS inflammation beyond NASH.
The clinical study results show;
First-in class anti-LPS mechanism of action confirmed for IMM-124E.
Excellent safety and tolerability.
Statistically significant reduction in serum endotoxin/lipopolysaccharide (LPS) levels compared to placebo.
Statistically significant reduction in mean serum ALT in patients with elevated pre-treatment ALT
Statistically significant reduction of additional serum NASH biomarkers associated with liver damage –AST and CK-18.
IMM-124E retained within the GI tract and not absorbed into the bloodstream, contributing to favourable safety profile.
Anti-LPS mechanism of IMM-124E may have wider therapeutic applications beyond NASH.
